2023 World Conference on Lung Cancer (Posters)-P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities

P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities - PDF(Abstract)

Back to course

Pdf Summary

This study examined the impact of comorbid heart diseases (HD) on treatment response and cardiotoxicity in stage IV non-small cell lung cancer (NSCLC) patients receiving targeted and immunotherapies. The researchers analyzed data from a 14-year clinical cohort of NSCLC patients and compared subgroups with HD, non-HD comorbidities, and none using T- or Chi-Square tests, treatment response analyses, and proportional hazard models. They identified 3768 eligible patients, of whom 1848 received systemic therapy including 862 with targeted and immunotherapy. Among the patients receiving targeted therapy, 1.6% developed cardiotoxicity, which was significantly associated with HD. The median survival of patients with cardiotoxicity was 4.9 years, higher than those without. Multivariable analysis showed that patients with cardiotoxicity had a lower risk of death compared to those without. The study also found that the incidence of cardiotoxicity was higher in patients treated with an epidermal growth factor receptor inhibitor (EGFRi) who had HD compared to those without HD. Patients treated with an anaplastic lymphoma kinase inhibitor (ALKi) and experienced cardiotoxicity had a lower risk of death compared to those without cardiotoxicity, after adjusting for HD, smoking status, response to therapy, and age. The researchers concluded that cardiotoxicity was more prevalent in patients with HD and that ALKi-associated cardiotoxicity might be a protective factor for patient survival. They suggested that further studies with larger samples are needed to investigate the biological and pharmacological mechanisms involved.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

comorbid heart diseases

treatment response

cardiotoxicity

stage IV non-small cell lung cancer

NSCLC patients

targeted therapies

immunotherapies

clinical cohort

systemic therapy

patient survival